BrightSpring Health Services, I (BTSG) Stock Analysis
Healthcare · Health Information Services
Sell if holding. Analyst target reached at $60.87 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: top-10 states (53.0%).
BrightSpring Health Services delivers home and community-based healthcare across Pharmacy Solutions (specialty/infusion/home dispensing, 43M+ prescriptions in 2025) and Provider Services (home health, hospice, rehab) segments, serving 465,000+ patients daily in all 50 states.... Read more
Sell if holding. Analyst target reached at $60.87 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: top-10 states (53.0%). Chart setup: No clear chart pattern; technical signals are mixed. Score 5.2/10, moderate confidence.
Passes 6/8 gates (clean insider activity, no SEC red flags, news events none recent, earnings proximity 52d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and favorable risk/reward ratio. Suitability: aggressive.
About BrightSpring Health Services, I
About BrightSpring Health Services, I
BrightSpring Health Services served over 465,000 patients daily across all 50 states in 2025, operating through more than 175 pharmacies and filling 43 million prescriptions during the year. The company's approximately 10,500 clinical providers and pharmacists also delivered 21 million hours of home health, hospice, rehab, and supportive care. Approximately 53% of revenues were concentrated in 10 states with favorable demographics and regulatory environments.
The company generates revenue through two segments: Pharmacy Solutions, which served over 410,000 patients through more than 4,500 unique customer and payor contracts across 6,600 customer locations in 2025; and Provider Services, which delivers clinical home health, hospice, rehab therapy, and personal care to approximately 16,000 Senior and Specialty patients. On March 30, 2026, BrightSpring completed the divestiture of its Community Living business to National Mentor Holdings for $835 million, narrowing Provider Services to clinical and supportive care. Payer mix is heavily weighted toward Medicare, Medicaid, and commercial insurance, with managed care organizations increasingly intermediating reimbursements under capitation models. The Pharmacy Solutions segment holds access to 149 limited-distribution oncology drugs with 18 more in the launch pipeline, creating preferred channel relationships with pharmaceutical manufacturers.
Show full overview
Medicare and Medicaid reimbursement risk is the dominant financial exposure: CMS can reduce base prospective payment rates, eliminate annual rate increases, change case-mix thresholds, or reclassify home health resource groups — each of which may impact revenue. The Review Choice Demonstration, running through 2029, subjects home health agencies in Illinois, Ohio, North Carolina, Florida, Oklahoma, and Texas to pre-claim review, increasing administrative costs and potentially delaying payments. With more than half of Medicare beneficiaries enrolled in Medicare Advantage plans as of January 2025, MCO contracts — terminable on 60 days' notice — add further rate pressure.
See also: Healthcare · Health Information Services
From BrightSpring Health Services, I's most recent 10-K filing, extracted June 9, 2026.
Recent developments
updated 2026-06-09Recent Developments — BrightSpring Health Services, I
Latest news
- NEWS BrightSpring Health Services, Inc. (BTSG) is on the Move, Here's Why the Trend Could be Sustainable - Yahoo Finance — Yahoo Finance positive
- NEWS BrightSpring Health Services (BTSG) Stock Analysis: Exploring Growth Amidst Strong Revenue Surge - DirectorsTalk Intervi — DirectorsTalk Interviews positive
- NEWS Are Options Traders Betting on a Big Move in BrightSpring Health Services Stock? - MSN — MSN neutral
- NEWS Here's why you should add BrightSpring stock to your portfolio now - MSN — MSN positive
- NEWS Goldman Sachs Initiates Coverage On BrightSpring Health with Buy Rating, Announces Price Target of $71 — benzinga Jun 8, 2026 positive
Generated 2026-06-15T18:11:46Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHGeographictop-10 states53%10-K Item 1: 'approximately 53% of our revenue in 10 states for the year ended December 31, 2025'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Analyst target reached at $60.87 — A.R:R is negative (-0.8) — price has exceeded the analyst target. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Concentration risk — Geographic: top-10 states (53.0%). Chart setup: No clear chart pattern; technical signals are mixed. Prior stop was $56.85. Score 5.2/10, moderate confidence.
Take-profit target: $60.87 (+0.1% upside). Prior stop was $56.85. Stop-loss: $56.85.
Concentration risk — Geographic: top-10 states (53.0%); Analyst target reached - limited upside remaining; Near 52-week high (2.1% away).
BrightSpring Health Services, I trades at a P/E of 76.9 (forward 28.0). TrendMatrix value score: 5.1/10. Verdict: Sell.
22 analysts cover BTSG with a consensus score of 4.3/5. Average price target: $62.
What does BrightSpring Health Services, I do?BrightSpring Health Services delivers home and community-based healthcare across Pharmacy Solutions...
BrightSpring Health Services delivers home and community-based healthcare across Pharmacy Solutions (specialty/infusion/home dispensing, 43M+ prescriptions in 2025) and Provider Services (home health, hospice, rehab) segments, serving 465,000+ patients daily in all 50 states. Revenue is primarily Medicare and Medicaid reimbursement with ~53% from 10 states. The March 2026 divestiture of the Community Living business for $835M sharpens focus on Senior and Specialty patient pharmacy and clinical care.